VERACYTE, INC. — Director's Dealing 2020

Jul 15, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERACYTE, INC. (VCYT)
CIK: 0001384101
Period of Report: 2020-07-13

Reporting Person: Kennedy Giulia C (Chief Scientific & Med Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-07-13	Common Stock	M	13498	$14.34	Acquired	93985	Direct
2020-07-13	Common Stock	M	1771	$9.05	Acquired	95756	Direct
2020-07-13	Common Stock	M	1469	$5.98	Acquired	97225	Direct
2020-07-13	Common Stock	S	724	$28.82	Disposed	96501	Direct
2020-07-13	Common Stock	S	15814	$29.6902	Disposed	80687	Direct
2020-07-13	Common Stock	S	200	$30.455	Disposed	80487	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-07-13	Stock Option (right to buy)	$14.34	M	13498	Disposed	2024-02-18	Common Stock (13498)	Direct
2020-07-13	Stock Option (right to buy)	$9.05	M	1771	Disposed	2027-03-02	Common Stock (1771)	Direct
2020-07-13	Stock Option (right to buy)	$5.98	M	1469	Disposed	2028-03-01	Common Stock (1469)	Direct

Footnotes

F1: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020.

F2: Represents weighted average sales price. Sale prices for the transactions range from $28.40 to $29.40. Detailed information regarding the number of shares sold at each separate price will be provided to the
SEC, the issuer or a shareholder upon request.

F3: Represents weighted average sales price. Sale prices for the transactions range from $29.41 to $30.38. Detailed information regarding the number of shares sold at each separate price will be provided to the
SEC, the issuer or a shareholder upon request.

F4: Represents weighted average sales price. Sale prices for the transactions range from $30.45 to $30.46. Detailed information regarding the number of shares sold at each separate price will be provided to the
SEC, the issuer or a shareholder upon request.

F5: The option is fully vested.

F6: The option becomes exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous
service thereafter.

F7: The option becomes exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous
service thereafter.